Every material Form 8-K H.B. Fuller filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
H.B. Fuller elected Celine Martin, a former Johnson & Johnson MedTech group chairman, as a Class III director effective December 1, 2025. The company said her medical industry experience supports its focus on high-margin medical markets and its goal of a greater than 20% EBITDA margin.
Celine Martin, age 51, elected by the Board on October 2, 2025, effective December 1, 2025; term expires at the 2026 annual meeting
Serves on the Audit and Compensation Committees; receives $100,000 annual cash retainer, initial grant of 1,300 restricted stock units, and eligibility for a $165,000 annual phantom stock grant
Board will have nine directors after December 1, 2025, eight of whom are independent
H.B. Fuller reported third-quarter fiscal 2025 results, with net revenue down 2.8% year-on-year to $892 million while adjusted EPS rose 12% to $1.26 on higher adjusted net income and fewer shares outstanding. The company tightened its fiscal 2025 guidance range, now expecting adjusted EPS of $4.10 to $4.25 and revenue down 2% to 3%, citing a subdued economic backdrop.
Q3 net revenue was $892 million, down 2.8%; up 1.6% excluding the flooring divestiture
Reported diluted EPS was $1.22 versus $0.98 a year earlier; adjusted diluted EPS was $1.26, up 12%
Adjusted EBITDA was $171 million, up 3%, with an adjusted EBITDA margin of 19.1%, up 110 basis points
Fiscal 2025 guidance: adjusted EPS $4.10 to $4.25, adjusted EBITDA $615 million to $625 million, revenue down 2% to 3%
H.B. Fuller reported second-quarter fiscal 2025 results for the quarter ended May 31, 2025, with net revenue of $898 million, down 2.1% year-on-year, and reported diluted EPS of $0.76, down from $0.91. Adjusted EPS rose 5% to $1.18, and the company raised its full-year adjusted EBITDA and adjusted EPS guidance, which matters to shareholders because the updated outlook reflects higher expected profitability on an adjusted basis even as reported results declined.
Net revenue was $898 million, down 2.1% year-on-year; adjusted for the flooring divestiture, it rose 2.8%.
Reported diluted EPS was $0.76 versus $0.91 a year earlier; adjusted diluted EPS was $1.18, up 5%.
Adjusted EBITDA was $166 million, up 5%, and adjusted EBITDA margin rose 130 basis points to 18.4%.
Fiscal 2025 adjusted EBITDA guidance is $615 million to $630 million and adjusted EPS guidance is $4.10 to $4.30.
H.B. Fuller reported first quarter 2025 results for the period ended March 1, 2025. Net revenue fell 2.7% to $789 million, although organic revenue rose 1.9%, and net income declined to $13 million from $31 million a year earlier. Adjusted EBITDA fell 7% to $114 million, which the company said was as expected, and the full-year 2025 outlook was left unchanged.
Net revenue was $789 million, down 2.7% year-on-year; organic revenue rose 1.9%, driven by volume and pricing
Net income was $13 million versus $31 million a year earlier; reported diluted EPS was $0.24 versus $0.55
Adjusted EBITDA was $114 million, down 7%; adjusted diluted EPS was $0.54 versus $0.67
Full-year 2025 outlook is unchanged, including adjusted EBITDA of $600 million to $625 million; second-quarter adjusted EBITDA is expected at $150 million to $160 million
H.B. Fuller reported a fourth-quarter 2024 net loss of $7 million, or $0.13 per diluted share, compared with net income of $45 million a year earlier, after a $38 million after-tax non-cash charge tied to the Flooring divestiture. For fiscal 2025 it expects net revenue to fall 2% to 4% but adjusted EBITDA of $600 million to $625 million and adjusted EPS of $3.90 to $4.20, and it is finalizing a plan to cut manufacturing facilities and warehouses for about $75 million in annualized savings by fiscal 2030.
Q4 2024 net revenue rose 2.3% to $923 million, but adjusted EBITDA fell 14% to $148 million and adjusted diluted EPS was $0.92, versus $1.32 a year earlier.
Fiscal 2024 net revenue was $3.57 billion, up 1.6%, while net income was $130 million, versus $145 million in fiscal 2023.
Fiscal 2025 guidance calls for net revenue down 2% to 4% and adjusted EPS of $3.90 to $4.20, up 2% to 9% from $3.84.
The manufacturing footprint plan would reduce facilities from 82 to 55 and North American warehouses from 55 to about 10 by the end of 2027, with about $150 million in incremental capital over five years.
H.B. Fuller preliminarily expects fiscal 2024 adjusted EBITDA of about $594 million, below its prior guidance of $610 million to $620 million given on September 25, 2024. The company cited weaker fourth-quarter demand, delayed orders, and higher raw material costs, and said the figures are unaudited and subject to change.
Preliminary fiscal 2024 net revenue of about $3.57 billion, adjusted diluted EPS of about $3.84, and adjusted EBITDA of about $594 million
Prior adjusted EBITDA guidance was $610 million to $620 million, communicated September 25, 2024
Expected cash flow from operations of about $300 million for the year
Full fiscal 2024 results are scheduled for release after the market close on January 15, 2025, with a conference call on January 16, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every H.B. Fuller filing is on SEC EDGAR ↗. 8-K briefs of other companies →